Europe Anaphylaxis Treatment Market

The Europe anaphylaxis treatment market is estimated to grow at a CAGR of 6.6% during the forecast period (2020-2027)  to reach a market value of USD XX million by 2027.

Germany, France, U.K., Switzerland and Austria are some of the key markets in Europe with high prevalence of anaphylaxis admissions and higher growth in cases. According to European Anaphylaxis Registry, the total number of refractory anaphylaxis in the region is recorded just below 15,000 in 2020. This growth in the prevalence of anaphylaxis is driving the growth of anaphylaxis treatment market.

Also, the medical regulatory agencies in the region are conducting programs for rising awareness towards the allergic reaction and use of epinephrine. Drug and food are the primary causes of anaphylaxis in Europe. Fruits are the major cause of food-based anaphylaxis in the region

Epinephrine is considered as the only medication for front-line treatment of anaphylaxis that can reverse severe anaphylactic symptoms. The epinephrine market in the region is largely dominated by Mylan’s EpiPen auto-injectable epinephrine. 

Moreover, the company is offering the formulation at significantly lower prices in Europe in comparison to the U.S. market. The cost of a two-pack EpiPen is recorded in U.S. at USD 610 in 2019. However, the same dose is made commercially available at nearly USD 68 in U.K., USD 100 in France and USD 200 in Germany

U.K. evolved as the most lucrative market owing to rapidly growing anaphylaxis cases in the country.  Over 30% of its population are found to be prone to some sort of allergic response in their lifetime. The country recorded 5,497 admissions for anaphylactic reactions in 2019 which is 34% higher than 4,107 cases in 2014. London evolved as the major spot of the anaphylaxis with 480 new cases in 2019, witnessing an increase of 167% over 2014-2019

Drug hypersensitivity is the most common cause of anaphylaxis in U.K. According to several industry estimates, drugs are responsible for nearly 43% of all recorded anaphylaxis cases

The National Institute for Health and Care Excellence (NICE) has commissioned guidelines for the care of anaphylaxis population in the country. Quality standard [QS119] includes care for all age groups after emergency treatment for anaphylaxis

The market for anaphylaxis treatment in U.K. valued USD 235.6 million in 2019 and is estimated to reach USD XX million by 2027, growing at a CAGR of 7.1% during 2020-2027

The vaccination of “Pfizer-BioNTech COVID-19 Vaccine” for novel coronavirus is turning as the new venue for anaphylaxis in the region. Two of the first people administered with Pfizer’s vaccine in the U.K. showed an allergic reaction. Furthermore, the Wall Street Journal quoted “Regulator says people with history of significant allergic reactions shouldn’t get the shot”

Supply shortages associated with epinephrine auto-injectors and product recalls owing to their failure in activation are some of the hindering factors for anaphylaxis treatment market in the region. The market is highly dependent on EpiPen and some other brands such as Emerade (Bausch & Lomb) and Jext (ALK-Abelló Ltd.). In December 2019, the manufacturer of Emerade Autoinjectors recalled all unexpired batches throughout U.K in response to a reported case of activation failure 

Germany is the largest regional market for anaphylaxis treatment in Europe with a sales revenue of USD XXmillion in 2019. The incidence rate of anaphylaxis is estimated at 2-3 cases per 100,000 population per year

Analgesic drugs, animal proteins, legumes and insect stings are the primary causes for anaphylaxis in the country. Intramuscular administration of epinephrine is recommended as the first-line treatment for anaphylaxis. The efficiency in use of antihistamines and corticosteroids as additional treatment has low evidences.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com